https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45243 1H nuclear magnetic resonance, dynamic light scattering (DLS), and transmission electron microscopy techniques. The CT-capped gold nanoparticles (CTAuNPs) were prepared from CT, chloroauric acid, and NaBH₄. The CTAuNPs were characterized using ultraviolet–visible, high-resolution TEM, DLS, and Fourier transform IR techniques. The cytotoxicity and apoptosis-inducing ability of both nanoparticles were determined in HepG2 cells. The results demonstrate that CTNs exhibit antiproliferative activity in the cancerous HepG2 cells. Moreover, molecular docking and molecular dynamics studies were conducted to explore the therapeutic potential of CT against human EGFR suppressor protein to gain more insights into the binding mode of the CT, which may show a significant role in anticancer therapy.]]> Wed 26 Oct 2022 15:56:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45239 1H nuclear magnetic resonance, dynamic light scattering (DLS), and transmission electron microscopy techniques. The CT-capped gold nanoparticles (CTAuNPs) were prepared from CT, chloroauric acid, and NaBH₄. The CTAuNPs were characterized using ultraviolet–visible, high-resolution TEM, DLS, and Fourier transform IR techniques. The cytotoxicity and apoptosis-inducing ability of both nanoparticles were determined in HepG2 cells. The results demonstrate that CTNs exhibit antiproliferative activity in the cancerous HepG2 cells. Moreover, molecular docking and molecular dynamics studies were conducted to explore the therapeutic potential of CT against human EGFR suppressor protein to gain more insights into the binding mode of the CT, which may show a significant role in anticancer therapy.]]> Wed 26 Oct 2022 15:56:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47745 Wed 25 Jan 2023 15:49:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46370 Wed 16 Nov 2022 08:45:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47141 Wed 14 Dec 2022 15:27:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53640 Wed 13 Dec 2023 10:34:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53698 Wed 10 Jan 2024 10:49:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44025 1), Compritol® 888 ATO (X₂) and equal ratio of poloxamer 188: sodium taurocholate (% w/w) (X₃) on particle size, zeta potential and entrapment efficiency. The optimised formulation (SLN₈) was found to be spherical in shape with mean particle size 187.9 ± 10.73 nm and zeta potential −47.4 mV. The maximum percentage entrapment of RIF, INH and PYZ in the optimised formulation was found to be 86.40 ± 0.274, 83.84 ± 0.269 and 81.43 ± 0.576, respectively. The in-vitro drug release study demonstrated that the release of drug from SLNs was slow in comparison to marketed formulation and pure ATDs. Cytotoxicity of the ATDs-SLNs was studied on murine macrophage cell line (RAW 264.7) using modified MTT assay demonstrated two folds growth inhibition of M. marinum as compared to standard antitubercular drugs. Overall, the developed SLNs may be considered as a promising anti-mycobacterial nano-drug, providing a new direction to the tuberculosis clinics.]]> Wed 05 Oct 2022 15:25:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46354 Tue 15 Nov 2022 14:40:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38437 Mon 29 Jan 2024 18:01:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49577 Mon 22 May 2023 10:51:01 AEST ]]>